Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Chugai Pharmaceutical Co ( (JP:4519) ).
Roche announced its third-quarter sales for 2025, which includes the performance of its subsidiary, Chugai Pharmaceutical Co., Ltd. This announcement highlights Chugai’s integral role within the Roche Group, reflecting its impact on the overall financial results and strategic positioning in the pharmaceutical market.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen8050.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, primarily focused on the development and marketing of innovative drugs. As a subsidiary of Roche Holding Ltd., Chugai benefits from a strong market presence and extensive research capabilities, contributing significantly to the healthcare sector.
Average Trading Volume: 3,668,937
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen11610.1B
See more data about 4519 stock on TipRanks’ Stock Analysis page.